Mecasermin Rinfabate Recombinant Patent Expiration
Mecasermin Rinfabate Recombinant is used for promoting linear growth in the treatment of primary IGF-1 deficiency. It was first introduced by Insmed Inc
Mecasermin Rinfabate Recombinant Patents
Given below is the list of patents protecting Mecasermin Rinfabate Recombinant, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Iplex | US5681818 | Therapeutic uses of human somatomedin carrier proteins |
Oct 28, 2014
(Expired) | Insmed |
Mecasermin Rinfabate Recombinant's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List